Vendor, Philadelphia, PA
The Institute for Cancer Research
UEI FF1XVJMDYVR1, CAGE 1RAF4
2 awards and -$16,800 obligated between July 6, 2026 and July 7, 2026, 50% under full and open competition, against 1.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Competed Under SAP | 1 |
| Delivery Order | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91022F00002Delivery Order, July 7, 2026, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Task Order TitlNAICS 541714, PSC AN12 | $0 |
| 75N92E21P00142Purchase Order, July 6, 2026, Competed Under SAP, 2 offers | National Institutes of Health NhgriNational Institutes of Health | The Elnitski Lab Is Purchasing Normal, Liver, and Prostate Cancer Patient Plasma.[21-004028]NAICS 541715, PSC 6505 | -$16,800 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research6505 Drugs and Biologicals
- Transactions
- 2 across 2 awards